December 9, 2013
ViiV Healthcare K.K. of the UK-based GlaxoSmithKlin (GSK) group announced on December 5 that it filed a new drug application (NDA) on the same day for its human immunodeficiency virus type 1 (HIV-1) integrase inhibitor dolutegravir sodium for the treatment...read more